Circassia Raises $333.5 Million in IPO for Allergy Vaccines
This article is for subscribers only.
Circassia Pharmaceuticals Plc raised about 200 million pounds ($333.5 million) in an initial public offering to help fund development of allergy vaccines.
Circassia sold 64.5 million shares at 310 pence each, and existing stockholders sold another 2.9 million, the Oxford, England-based company said in a statement today. The price was at the top of the range of 250 pence to 310 pence indicated last month by the banks arranging the sale.